DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
GLPG1205 is an investigational drug.
There have been 6 clinical trials for GLPG1205. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2014.
The most common disease conditions in clinical trials are Ulcer, Colitis, Ulcerative, and Colitis. The leading clinical trial sponsors are Galapagos NV and [disabled in preview].
There are two US patents protecting this investigational drug and forty-two international patents.
Recent Clinical Trials for GLPG1205
|A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Healthy Japanese and Caucasian Male Subjects||Galapagos NV||Phase 1|
|A Clinical Study to Test How Effective and Safe GLPG1205 is for Patients With Idiopathic Pulmonary Fibrosis (IPF)||Galapagos NV||Phase 2|
|A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects||Galapagos NV||Phase 1|
Top disease conditions for GLPG1205
Top clinical trial sponsors for GLPG1205
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|GLPG1205||Start Trial||Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders||Galapagos NV (Mechelen, BE)||Start Trial|
|GLPG1205||Start Trial||Dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders||GALAPAGOS NV (Mechelen, BE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|